AMRX: financial statements from SEC — TradeAlmanac

AMRX

Amneal Pharmaceuticals, Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	Mar 31, 2026	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Sep 30, 2024	Jun 30, 2024
Revenue	723m	785m	725m	695m	702m	702m
Cost of revenue	402m	511m	438m	440m	433m	452m
Gross profit	320m	274m	286m	256m	270m	250m
Research and development	38m	63m	48m	40m	61m	36m
Selling, general and administrative	139m	138m	124m	118m	119m	116m
Operating income	142m	70m	111m	100m	89m	95m
Pre-tax income	80m	−5m	52m	37m	15m	20m
Income tax	2m	−23m	16m	13m	4m	4m
Net income	62m	2m	22m	12m	−156,000	6m
Earnings per share	0.20	0.01	0.07	0.04	0.00	0.02
Earnings per share, diluted	0.19	0.01	0.07	0.04	0.00	0.02
Weighted average shares	316m	314m	314m	311m	310m	309m
Weighted average shares, diluted	329m	325m	322m	324m	310m	319m

Balance sheet

Metric	Mar 31, 2026	Dec 31, 2025	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024
Cash and equivalents	198m	282m	201m	72m	59m	111m	74m	44m
Inventory	642m	606m	615m

Cash flow

Metric	Mar 31, 2026	Mar 31, 2025
Operating cash flow	−27m	7m
Share-based compensation	9m	7m
Capital expenditure	8m	13m
Investing cash flow	−22m	−18m
Financing cash flow	−59m	−39m

Amounts in USD unless stated otherwise. Sources: Nasdaq Trader, Yahoo Finance, U.S. Securities and Exchange Commission (EDGAR)